Custom-Made vaccine plus immunotherapy shows promise in tough lung cancer
NCT ID NCT04397003
First seen Nov 01, 2025 · Last updated Jun 15, 2026 · Updated 30 times
Summary
This study tests a personalized vaccine (made from each patient's unique tumor markers) combined with the immunotherapy drug durvalumab for people with extensive-stage small cell lung cancer. The goal is to see if this combination is safe and can help slow cancer growth. Only 6 participants were enrolled, and the vaccine had to be made within 24 weeks of starting treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.